What is the history of Birt-Hogg-Dubé syndrome?

Birt-Hogg-Dubé syndrome (BHD) was first described in 1977 by physicians Arthur R. Birt, Georgina M. Hogg, and William J. Dubé, who identified the condition through its characteristic skin lesions. Since the discovery of the causative FLCN gene in 2002, our understanding has evolved from viewing it primarily as a dermatological curiosity to recognizing it as a multisystem genetic disorder involving significant risks for renal tumors and pulmonary cysts.

How was Birt-Hogg-Dubé syndrome first identified?

In 1977, Canadian dermatologists Arthur Birt, Georgina Hogg, and William Dubé published a landmark paper in the Archives of Dermatology. They described a family exhibiting multiple skin tumors, which they termed fibrofolliculomas, along with acrochordons and connective tissue nevi. Initially, the medical community viewed Birt-Hogg-Dubé syndrome as a rare skin condition characterized by these benign facial papules. It was not until the 1980s and 1990s that clinicians began to notice a recurring pattern of patients with these specific skin findings also presenting with spontaneous pneumothorax (collapsed lungs) and an increased susceptibility to renal cell carcinoma.

How has our understanding of Birt-Hogg-Dubé syndrome evolved?

The field underwent a paradigm shift in 2002 when researchers identified the FLCN gene (folliculin) on chromosome 17p11.2 as the culprit behind Birt-Hogg-Dubé syndrome. This discovery moved the condition from the realm of descriptive dermatology into the field of molecular genetics. We now understand that FLCN acts as a tumor suppressor gene. When this gene is mutated, the body’s cells lose a critical regulatory mechanism, leading to the development of cysts in the lungs and various types of kidney tumors. Today, Birt-Hogg-Dubé syndrome is formally classified as a rare autosomal dominant inherited disorder, meaning a child of an affected individual has a 50% chance of inheriting the mutation.

What were the major milestones in the clinical history of the disease?

The progression of medical knowledge regarding Birt-Hogg-Dubé syndrome can be summarized by these key milestones:

• 1977: First clinical description of the triad of fibrofolliculomas, acrochordons, and connective tissue nevi.


• 1986: First report linking the syndrome to renal cell carcinoma, establishing the need for long-term cancer surveillance.


• 1999: Recognition of the association between the syndrome and spontaneous pneumothorax, caused by cystic lung disease.


• 2002: Identification of the FLCN gene, enabling definitive genetic testing for families.


• 2010s-Present: Implementation of international surveillance protocols for kidney imaging and pulmonary monitoring.

How has patient advocacy changed the landscape for those affected?

Historically, patients were often misdiagnosed or treated for isolated symptoms—such as having a lung collapse or a kidney mass—without the realization that these events were connected. The growth of global patient advocacy, including the 114 members currently sharing their experiences on DiseaseMaps.org, has been instrumental in connecting patients with specialists. This community-driven awareness has helped correct the misconception that Birt-Hogg-Dubé syndrome is merely a "skin disease," pushing it to the forefront of renal and pulmonary research where it belongs.

Next steps

• Consult with a clinical geneticist to discuss genetic testing if you or your family members suspect Birt-Hogg-Dubé syndrome.


• Establish a relationship with a nephrologist or urologist familiar with the surveillance protocols for Birt-Hogg-Dubé syndrome.


• Join a dedicated patient support group, such as the BHD Foundation, to stay updated on emerging research and clinical trials.


• Ensure your primary care physician is aware of the specific need for baseline chest imaging and regular renal monitoring.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the guidance of a qualified healthcare professional regarding any medical condition.

References

• Orphanet: Birt-Hogg-Dubé syndrome (ORPHA:125)


• NIH Genetic and Rare Diseases Information Center (GARD): Birt-Hogg-Dubé syndrome


• Online Mendelian Inheritance in Man (OMIM): #135150


• The BHD Foundation: Research and Patient Resources